Next Article in Journal
Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling
Previous Article in Journal
Glioblastoma in Elderly Patients: Current Management and Future Perspectives
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Cancers 2019, 11(3), 337; https://doi.org/10.3390/cancers11030337

Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis

1
Molecular Cancer Biology Laboratory, Cellular Heterogeneity Research Center, Department of Biosystem, Sookmyung Women’s University, Hyochangwon gil-52, Yongsan-Gu, Seoul 140-742, Korea
2
Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India
*
Author to whom correspondence should be addressed.
Received: 27 January 2019 / Revised: 23 February 2019 / Accepted: 1 March 2019 / Published: 8 March 2019
Full-Text   |   PDF [6762 KB, uploaded 8 March 2019]   |  

Abstract

SERTAD/TRIP-Br genes are considered as a key nuclear transcriptional player in diverse mechanisms of cell including carcinogenesis. The Oncomine-Online Platform was used for differential expression and biological insights. Kaplan-Meier survival estimated by KM-plotter/cBioPortal/PrognoScan with 95% CI. SERTAD1 was found significantly elevated levels in most of tumor samples. Kaplan-Meier Plotter results distinctly showed the SERTAD1 over-expression significantly reduced median overall-survival (OS) of patients in liver (n = 364/Logrank-test p = 0.0015), ovarian (n = 655/Logrank-test p = 0.00011) and gastric (n = 631/Logrank-test p = 0.1866). Increased level of SERTAD1 has a significantly higher survival rate in the initial time period, but after 100 months slightly reduced OS (n = 26/Logrank-test p = 0.34) and RFS in HER2 positive breast cancer patients. In meta-analysis, cancer patients with higher SERTAD1 mRNA fold resulted worse overall survival than those with lower SERTAD1 levels. Heterogeneity was observed in the fixed effect model analysis DFS [Tau2 = 0.0.073, Q (df = 4) = 15.536 (p = 0.004), I2 = 74.253], DSS [Tau2 = 1.015, Q (df = 2) = 33.214, (p = 0.000), I2 = 93.973], RFS [Tau2 = 0.492, Q (df = 7) = 71.133 (p = 0.000), I2 = 90.159] (Figure 5). OS [Tau2 = 0.480, Q (df = 17) = 222.344 (p = 0.000), I2 = 92.354]. Lastly, SERTAD1 involved in several signaling cascades through interaction and correlation with many candidate factors as well as miRNAs. This meta-analysis demonstrates a robust evidence of an association between higher or lower SERTAD1, alteration and without alteration of SERTAD1 in cancers in terms of survival and cancer invasiveness. View Full-Text
Keywords: SERTAD1; overall survival; disease/relapse free survival; mutation; correlation; protein interaction; meta-analysis; miRNAs SERTAD1; overall survival; disease/relapse free survival; mutation; correlation; protein interaction; meta-analysis; miRNAs
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Mongre, R.K.; Jung, S.; Mishra, C.B.; Lee, B.S.; Kumari, S.; Lee, M.-S. Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis. Cancers 2019, 11, 337.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top